Hirabatake, Masaki
35  results:
Search for persons X
?
 
?
 
?
3

Pharmacist–Urologist Collaborative Management for Patients ..:

Hirabatake, Masaki ; Ikesue, Hiroaki ; Yoshino, Shintaro...
Biological and Pharmaceutical Bulletin.  46 (2023)  8 - p. 1065-1071 , 2023
 
?
4

Impact of prior bevacizumab therapy on the incidence of ram..:

Dote, Satoshi ; Shiwaku, Eiji ; Kohno, Emiko...
International Journal of Clinical Oncology.  28 (2023)  8 - p. 1054-1062 , 2023
 
?
5

Risk Factors of Proteinuria in Patients with Hepatocellular..:

Ikesue, Hiroaki ; Yamamoto, Haruna ; Hirabatake, Masaki...
Biological and Pharmaceutical Bulletin.  45 (2022)  3 - p. 333-338 , 2022
 
?
8

Population Pharmacokinetics of Nivolumab in Japanese Patien..:

Tohi, Makiko ; Irie, Kei ; Mizuno, Tomoyuki...
Therapeutic Drug Monitoring.  45 (2022)  1 - p. 110-116 , 2022
 
?
9

Risk factors of proteinuria and potentially protective effe..:

Ikesue, Hiroaki ; Yamaoka, Kenta ; Matsumoto, Ayako...
Cancer Chemotherapy and Pharmacology.  89 (2022)  6 - p. 833-838 , 2022
 
?
10

Evaluating the safety and efficiency of robotic dispensing ..:

Takase, Tomoki ; Masumoto, Norio ; Shibatani, Naoki...
Journal of Pharmaceutical Health Care and Sciences.  8 (2022)  1 - p. , 2022
 
?
 
?
12

Switching from zoledronic acid to denosumab increases the r..:

Ikesue, Hiroaki ; Doi, Kohei ; Morimoto, Mayu...
Cancer Chemotherapy and Pharmacology.  87 (2021)  6 - p. 871-877 , 2021
 
?
13

Safety evaluation of enzalutamide dose-escalation strategy ..:

Miura, Rieko ; Hirabatake, Masaki ; Irie, Kei...
Urologic Oncology: Seminars and Original Investigations.  39 (2021)  4 - p. 233.e15-233.e20 , 2021
 
?
 
1-15